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ABSTRACT 
This essay has discussed various ways by which two or more than two drugs have been combined with Camptothecin through 
nanoparticles in order to yield anti-cancer therapy effectiveness. A systematic and comprehensive literature review has been 
prepared to show such combinations demonstrated high anticancer efficacy. 
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INTRODUCTION 
Camptothecin, (CPT) as well as its various analogues, is 
regarded as anticancer drugs of most promising nature.
1-
3
 The drugs are such that they result in targeting the 
topoisomerase which is a nuclear enzyme. 
4,5
 CPTs, 
however, are problems to be clinically applied.
6
 This is 
because they do not have adequate solubility in water 
and are not stable when PH is neutral. This results in 
deactivating CPTs through conversion of CPT from its 
lactone form to its form of carboxylate.
7-9
 This is 
possible by combining CPT with other drugs that assist 
CPT to deal with its drawbacks.
10-12
 This paper takes 
into consideration the various combination components 
that can be used to combine with CPTs in order to prove 
their effectiveness as anti-cancer drugs.
13-15
 This is done 
by regarded various literature articles popular in the 
field. 
Camptothecin + Doxorubicin via Folding graft 
copolymer 
According to the article by Wanyi Tai et al.
16
, folding 
into nanostructures is possible with pendant drug 
segments and graft copolymer. In order to construct a 
graft copolymer, polymerization of ŷ-camptothecin-
glutamate N-carboxy anhydride over several poly- 
ethylene glycol sites is done. This is dependent upon the 
key chain through the polymerization process of ring 
open). The CPT or the camptothecin in this situation is 
an agent of anti-cancer with simple conjugation. The 
nature of such a CPT is hydrophobic in nature.
17,18
 It 
serves as the key dynamic force throughout the process 
of folding. When exposure of this comes in with water, 
the copolymer is gained.
19
 Doxorubicin then results in 
being folded into nanocarriers which can be 
monodispersed for delivery of the dual drug. Good 
stability is depicted by the nano-carriers as they have 
proper PEG shell equipment. The nano-carriers could be 
internalized through several cell lines of cancer through 
the endocytic pathway mediated through clathrin and 
lipid raft without the leakage of premature nature. 
20
 
This depicted a higher CPT based synergetic activity as 
well as Dox in the direction of several cells of cancer. 
The article further showed the validation through “in 
vivo” study exhibiting an accumulation of strong nature 
within the sites of tumor. It went on to show an activity 
of anti-cancer prominently in the opposite xenograft 
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with the model of xenograft mice in comparison to free 
drugs.  
Camptothecin + Doxorubicin via Supramolecular 
Hydrogel 
According to the article by Zhang et al.
21
, another 
method has been explored for sustaining therapy of 
synergistic tumor. The article states that multiple drugs 
co-delivery has become the key strategy for the therapy 
of cancer in the recent times.
22,23
 This is because the 
process can lead towards promoting actions of 
synergistic nature. The process also results in reducing 
any side influences and deters drug resistance 
development. For achieving loaded drugs controlled and 
sustained release, the hydrogel of supramolecule base is 
taken on the basis of interactions between host and 
guest.
24,25
 The interactions take place between 
derivatives of polyglycerol hyper-branching as well as 
alpha-cyclodextrin. The alpha-cyclodextrin preparation 
was done and it was utilized for co-loading the 
camptothecin as well as doxorubicin for sustaining the 
therapy of synergistic tumor. The kinetics of gelation, 
the strength of hydrogel as well as the obtained hydrogel 
supra-molecular structure were taken into consideration. 
This was done through the process of rheometry which 
was both dynamic and steady under several alpha CD 
concentrations. The supramolecular hydrogel leads 
towards releasing dual drug sustainability. This is shown 
in the article through in-vitro studies. The exploration 
was done in the article for their synergistic influences in 
vivo and vitro. The supramolecular hydrogel depicted 
compatibility of receivable blood and non-cytotoxicity 
through the assays of in vitro and in vivo. It was clear 
that sustaining tumor therapy synergistic is possible 
through the supra-molecule hydrogel.  
Camptothecin and curcumin by cationic polymeric 
nanoparticles 
In the article by Xiao et al.
26
, another potent strategy has 
been explored. In this strategy, the chemotherapy 
process is done using combination based on 
nanoparticles to enhance concentrations of the drug 
intracellularly. This allows for the achievement of 
synergistic influences within the therapy of colon 
cancer. In this, fabrication was done of several CPTs 
with chitosan functionalization.
27
 This illustrated various 
CPT and CUR ratios. The result was a CPT with the 
cationic sphere with a desired size of the particle at 193 
to 224 nm. This had a relatively distributed small size 
and slight zeta potential positivity. Such nanoparticles 
depicted a sustainability of simultaneous nature with 
releasing profile for the drugs across the period of 
research with the light release of the first burst. 
Experiments subsequently with the uptake of cells 
depicted through chitosan introduction to the surface of 
NP-led towards increasing the efficiency of cellular 
uptake in comparison with the formulation of other 
drugs. This, therefore, enhanced the synergistic 
influences from the drugs. The testing of 5 cationic 
CPTs was done. CPTs with nanoparticles had a 
weighing ratio with 4:1. This depicted the highest 
activity of anti-cancer. This resulted in an index of 
combined nature at 0.46. The study represented the 
initial report of combined CPT and CUR application 
with initial step fabrication system consisting of co-
delivery. This was done for the effectiveness of 
combined chemotherapy for colon cancer.  
Co-delivery of 10-Hydroxycamptothecin with 
Doxorubicin Conjugated Prodrugs 
In the article by Zhang et al.
28
, properly defined 
prodrugs with amphiphilic linear- dendritic synthesis are 
done. This is done by doxorubicin conjugation towards 
MPEG-b-PAMAM by the hydrazine bond of acid-labile. 
29
The prodrugs with amphiphilic nature for nano-
particles of the self-assembled form are used. This 
happens in water with deionization. This results in 
encapsulating the anticancer drug having a hydrophobic 
nature. The drug is namely 10-hydroxycamptothecing 
with the efficiency of higher drug loading. Drug release 
and cell uptake studies of the system of co-delivery 
depicted that these drugs get released in a manner that is 
dependent on pH. They are taken up effectively through 
the cells of MCF-7. Nanoparticles loaded with HCPT 
result in suppressing the growth of cancer cells in a 
much efficient manner than the prodrugs named, 
MPEG-bPAMAM-DOX. HCPT loaded nano-cells are 
better than free HCPT, MPEG-b-PAMAM-DOX 
physical mixtures as well as HCPT with DOX 
equivalence. This has been demonstrated in the article 
through in-vitro assay apoptosis tests in which drugs 
namely methyl thiazolyl tetrazolium, were induced. The 
article reports that nanoparticles based on polymers can 
result in facilitation for solving the solubility issue of 
CPTs and for protecting these from degrading 
prematurely.  
The article takes into consideration that studies have 
shown not to make use of individual drugs for 
chemotherapeutics. These drugs have no efficiency and 
several limitations when viewing them to treat cancers. 
The restrictions are inclusive of drug resistance 
development, high toxic level and limited clinical usage 
regime.
30,31
 Nanocarriers with pH sensitivity have 
mostly gained more attention since distinct levels of pH 
are exhibited by the tumor in comparison to tissues 
which are healthy. In the situation where polymer-drugs 
are involved, conjugation is formed through co-polymer 
amphiphilic blocks. These are known as pro-drug 
polymeric. This is the responsive component.  
A Convergent Synthetic Platform for combination 
delivery of Cisplatin, Doxorubicin, and 
Camptothecin 
As per the article by Liao et al.
32
, another potential 
combination for therapy of cancer has been offered. The 
article states that combined therapy of cancer with basis 
on nano-particle can overcome traditional systemic 
therapies toxic and poor control. Therefore, the article 
offers a solution. It states that polymer therapeutics 
synthesis with control load capability and capacity of 
multiple therapeutic agents’ synchronized release is a 
key challenge. It is not only a challenge for delivery of 
the drug, but also for the chemistry of synthetic 
polymer. In the article, the authors have reported 
polymer based nanoparticles synthesis. These particles 
carry specific doxorubicin molar ratios, cisplatin, and 
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camptothecin. The article has provided an initial 
example for three drugs orthogonal trigger release from 
individual nanoparticles. The approach of great 
convergence synthetics opens a pathway for new 
combinational therapies based on NP as anti-cancer 
drugs. 
33
 
A cross-link design was taken in this article where more 
focus was on derivatives of diester with Pt (IV). These 
were applied widely in the form of pro-drugs for 
chemotherapeutic cisplatin clinical approval. Kinetics is 
then released to help enhance the effectiveness of the 
procedure. The selection was based on specific tests 
confirming the usage as well as application.  
CONCLUSION  
This is to conclude that nanoparticles have the ability to 
serve as anti-cancer drugs with efficiency. However, 
without combining them with other particles, this is not 
possible. When two or more than two drugs are 
combined, it results in promoting synergistic effects 
between distinct drugs in opposition to cells of cancer. It 
also results in suppressing the resistance of drugs by 
different action mechanisms. Delivery of nanoparticle 
drugs, on the contrary, helps in enhancing the 
effectiveness of therapy and reducing drug payloads side 
effects through pharmacokinetics. This paper has 
summarized recently combined therapies proposed for 
anti-cancer drugs efficiency and the therapy of cancer 
efficiently. 
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